Patients with esophageal adenocarcinoma with MDM2 amplification showed a poor treatment response followed by neoadjuvant therapy in a retrospective trial, resulting in a significantly worse progression-free survival of these patients [22]. This evidence concerns the gene MDM2 and esophageal adenocarcinoma.